Tags:CommerceDevelopmentDrugHealthTechMarketMedtechPlatformProductResearchTechnology
Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology - Symphogen’s strategic focus is to apply our streamlined and effective antibody platform and capabilities in the discovery and early development of highly differentiated antibodies. The aim is to develop novel compounds either as combination or as stand-alone therapies for difficult to treat cancers.
Location: Denmark, Capital Region of Denmark, Måløv
Member count: 51-200
Total raised: $431.697039M
Founded date: 2000

Investors 2

Funding Rounds 4

DateSeriesAmountInvestorsDeal News
22.10.2015-$74.965765...-finsmes.co...
02.05.2013-$184.04163...-gildehealt...
06.01.2011-$130.28518...-gildehealt...
04.02.2009-$42.404461...-gildehealt...

Mentions in press and media 9

DateTitleDescriptionCategoryAuthorSource
18.08.2016Essex Wood...COPENHAGEN, Denmark–(BUSINESS ...--citybizlis...
23.10.2015Symphogen ...Symphogen, a Copenhagen, Denma...Denmark-finsmes.co...
22.10.2015Symphogen ...Copenhagen, Denmark – Symphoge...--gildehealt...
03.05.2013Symphogen ...Symphogen, ­­­­­­a Copenhagen,...Denmark f...-finsmes.co...
02.05.2013Symphogen ...Copenhagen, Denmark – Symphoge...--gildehealt...
02.04.2012Symphogen ...Symphogen, a Copenhagen, Denma...Denmark f...-finsmes.co...
06.01.2011Symphogen ...Symphogen, a Copenhagen, Denma...Denmark-finsmes.co...
06.01.2011Symphogen ...UTRECHT, Netherlands – Symphog...--gildehealt...
04.02.2009SYMPHOGEN ...COPENHAGEN, Denmark - Symphoge...--gildehealt...